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Background: Bufothionine is an alkaloid in Cinobufacini (Huachansu). This study aims to investigate the effects of
bufothionine on liver tumors and acute liver injury.
Methods: In the hepatoprotective experiment, fifty rats were randomly divided into five groups (n = 10): normal
saline group, model group, compound glycyrrhizin injection (9.14 mL/kg); cinobufacini injection (3.42 mL/kg) (InjA) and
bufothionine (9.77 mL/kg) (BufoA) group. Liver weight indices were recorded to judge the degree of liver swelling,
hematoxylin and eosin (H&E) staining of liver tissues was carried out to observe liver histological morphology injury
and biochemical indicators including aspartate aminotransferase (AST); alanine aminotransferase (ALT); alkaline
phosphatase (ALP); and total bilirubin (TBIL) were determined by modular auto-analyzer. In anti-tumor experiment,
H22-tumor-bearing mice were randomly divided into five groups (n = 10): normal saline group, model group, cinobufacini
injection (InjB) (5.14 mL/kg), bufothionine (8.02 mL/kg) (BufoB) and 5-fluorouracil (5-Fu) (3.42 mL/kg). Tumors were
picked out and determined with vernier calipers. Histological morphology of tumors was observed by H&E
staining. In SMMC-7721 cells, expressions of proteins related to mitochondria-mediated apoptosis pathway including
Bcl-2, Bax, caspase-3, caspase-9, cyto-c, Bid, and p53 were analyzed by western blotting at low, medium,
high concentrations of bufothione (3.62 μg/mL, 18.12 μg/mL,90.62 μg/mL).
Results: Butothionine relieved CCl4-induced liver morphology, decreased the level of ALT (P =2.46 × 10
-2) and
expressed tendency to decrease other biochemical markers including AST, ALP and TBIL. Butothionine could also
promote necrosis of tumor tissue in H22-tumor-bearing mice and restrained tumor growth with 65.16% inhibition rate.
Its mechanism might relate to up-regulation of p53 (at low, mediate and high concentration, corresponding P values were
0.142, 0.0257, 0.0162), caspase-3 (P = 0.246, 0.0267 and 0.0236), cyto-c (P = 0.276, 0.0343 and 0.0429), Bid (P = 0.0125, 0.0395
and 0.0132) and Bax (P = 0.563, 0.0492 and 0.0357) in a dose-dependent manner, down-regulation of Bcl-2 expression
(P = 0.0232, 0.0178 and 0.0464), but had no significant effects on caspase-9 (P = 0.253, 0.147 and 0.287).
Conclusion: Bufothionine induced the proteins for the mitochondria-mediated apoptosis that inhibits liver tumors and
protects the liver against acute injury.Background
Cinobufacini (Huachansu), extracted from the skins and
parotid venom glands of the toad Bufobufo gargarizans
Cantor, is a Chinese medicine for treatment of swelling,
pain, and heart failure [1]. In recent years, cinobufacini
injection has also been widely used in clinics with or
without chemotherapy for various cancers such as lung
cancer, liver cancer, prostate cancer and gallbladder cancer* Correspondence: 2479707904@qq.com
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unless otherwise stated.with significant effects [2-9]. Bufadienolides are known to
be the main active compounds in cinobufacini [10-12] and
these compounds have cardiotonic, anesthetic, and
antineoplastic effects as well as stimulatory effects on
blood pressure and the respiratory system [13]. However,
bufadienolides belong to the cardioactive steroids and
may cause adverse heart reactions including arrhythmias,
ventricular ectopy, sinus bradycardia, atrial arrhythmias,
and hyperkalemia [14], which might limit the clinical
application of cinobufacini injection [15]. Therefore, it
is necessary to investigate the chemical ingredients
and effects of cinobufacini injection.s is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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compound in the cinobufacini injection (Figure 1A).
Meanwhile, bufadienolides such as cinobufagin and resibu-
fogenin (Figure 1B–D) were under the detection limits.
Bufothionine could also inhibit the proliferation of
human hepatocellular carcinoma cell lines in a dose-
and time-dependent manner, similar to cinobufagin
and resibufogenin [16], indicating that bufothionine
might be the active component of cinobufacini injection
against cancer.
This study aims to investigate the effects of bufothionine
on liver tumors and acute liver injury. The effects on
protecting liver function were evaluated by rats with
acute liver injury induced by carbon tetrachloride
(CCl4) and the effects on inhibiting liver cancer were
assessed by H22-tumor-bearing mice. The possible
mechanism through the mitochondria-mediated apoptotic
signaling pathway was also explored.
Methods
Bufothionine (Lot: 100201/01–04) and cinobufacini
injection (500 mg/mL) (Lots: 090315–2, 090322–2
100614–2) were provided by Jing Chan Pharmaceutical Co.
Ltd. China). Glycyrrhizin injection was purchased from
Minophagen Pharmaceutical Co. LTD (Japan). CCl4 and
dimethyl sulfoxide (DMSO) were provided by Sinopharm
Chemical Reagent Co. Ltd. (China) and Sangon Biotech
(Shanghai) Co. Ltd. (China), respectively.Figure 1 Structures of bufothionine. (A), buffalin (B), cinobufagin (C), anAnimals
Male Sprague–Dawley rats weighing 170–200 g and
male Kunming mice weighing 20–22 g were purchased
from Shanghai Laboratory Animals Ltd (China). The
animals were maintained at constant temperature
(21 − 25°C) and humidity (50 − 70%) on a 12-h/12-h
light/dark cycle with free access to food and water.
The animals were allowed to adapt to the laboratory
environment for at least 7 days prior to the experiments.
All procedures were performed according to the
guidelines of the National Animal Welfare Law of
China. The Experimental Animal Ethical Committee
of Shanghai University of Traditional Chinese Medicine
care guidelines were complied with to ensure that the
mice received human care (Ethics Approval Number:
SCXK2012–0002, 2012.1.30).Drug preparations
For rats in hepato-protective experiments, 8.4 mg of
bufothionine were dissolved in 200 μL of DMSO and
diluted with 140 mL normal saline. The final con-
centration of bufothionine was 58.57 μg/mL. For
H22-tumor-bearing mice in the anti-hepatocellular
carcinoma experiments, 4.5 mg of bufothionine were
dissolved in DMSO and diluted with 70 ml normal
saline. Obtained concentration of bufothionine was
64.29 μg/mL.d resibufogenin (D).
Xie et al. Chinese Medicine  (2015) 10:5 Page 3 of 11Acute liver injury test
Fifty rats were randomly divided into 5 groups (10 rats
each group) by random digit table generated by SPSS
17.0 software. (SPSS Inc., USA). Both the normal group
(Nor) and the model control group (Mod) were treated
with intraperitoneal injection of normal saline (including
0.3% DMSO). The rats in the three drug groups were
intraperitoneally injected with the corresponding drugs as
follows: compound glycyrrhizin injection (9.14 mL/kg)
(Gly); cinobufacini injection (3.42 mL/kg) (InjA) and
bufothionine (9.77 mL/kg) (BufoA).
All rats were treated once daily at a fixed time (09:00)
for 8 days. The weight, appearance and behaviors of each
rat including activities, diets and secretions were observed
and recorded daily. On day 8 th, CCl4 was administered at
the dosage of 1.5 mL/kg based on Yokohama et al. [17] at
15:00 o’clock to induce acute liver injury in each group
except for the normal control group. The rats were fasted
with free access to water for 18 h. On the following
day (day 9th) at 09:00, all rats were anesthetized with
diethylether to collect blood. The biochemical assays of
aspartate aminotransferase (AST); alanine aminotransferase
(ALT); alkaline phosphatase (ALP); and total bilirubin
(TBIL) were performed by a modular autoanalyzer (Roche,
Switzerland) [18]. The livers were also collected and
weighed. The obtained specimens were fixed in 10%
neutral-buffered formalin, dehydrated, and embedded in
paraffin for histo-chemical studies.
Cell lines and culture conditions
Mouse H22 hepatoma cells were purchased from American
Type Culture Collection (ATCC, USA). The SMMC-7721
cell line was obtained from the Shanghai Institute of Cell
Biology, Chinese Academy of Sciences (China). The two
cell lines were cultured in RPMI 1640 medium (Gibco,
USA) containing 10% heat-inactivated fetal bovine serum
(FBS) (Gibco, USA), penicillin (100 U/mL) (Gibco, USA)
and 100 mg/L streptomycin (Gibco, USA) at 37°C in
a humidified atmosphere of 5% CO2 in air. The cells
were subcultured every 2–3 days. All cell lines used for
experiments remained in the logarithmic growth phase.
H22-tumor-bearing mice test
H22 tumor cells were obtained from in vivo passages. The
stocked murine hepatoma H22 cells were subcultured in
RPMI 1640 containing 12% FBS and then collected into
blank RPMI 1640 culture medium (1 × 108 cells/mL).
About 0.2 mL of the cell suspension (approximately
2 × 107 cells) was injected into the abdominal cavity
of a mouse. At 5–7 days after the inoculation, ascites
occurred in the mice and the fluid was removed using
a plastic needle tube (5 mL) under aseptic conditions.
About 10–12 mL of fluid was collected from 2–3 mice.
The ascites fluid was diluted with an equal amount ofnormal saline, and centrifuged (Hettich Rotina 420
centrifuge, Germany) at 900 x g for 5 min under 4°C.
The pellet was mixed with 20 mL of normal saline.
Approximately 0.2 mL of the mixture (1 × 107 H22 cells)
was subcutaneously injected into the right flank of each
mouse. Cell mixture (10 mL) could be roughly inoculated
into 50 mice.
After 7 days, inoculated mice with tumor sizes of
100–150 mm3 were selected and randomly divided
into different groups (10–12 mice per group) by random
digit tablegenerated by SPSS 17.0 software. Twelve mice
without inoculation were characterized as the normal group
and injected with normal saline. Among the inoculated
groups, one group was injected with normal saline as the
model group (Mod) and the other groups were respectively
injected intraperitoneally with the following drugs:
cinobufacini injection (InjB) (5.14 mL/kg), bufothionine
(8.02 mL/kg) (BufoB) and 5-fluorouracil (5-Fu) (3.42 mL/kg).
The dosages of drugs for the animals were calculated
according to the human dosages recommended on
the package inserts. All mice were treated once daily
between 09:00 and 10:00 continuously for 10 days except
for the 5-Fu group, in which the drug was administered
twice a week. The appearances and behaviors were carefully
observed. Any abnormal situation such as diarrhea, irrita-
tion and emaciation should be recorded. Tumor sizes of
the animals were also measured with vernier calipers.
Tumor weight indices were expressed as the ratio of tumor
weight difference (final tumor weight - initial tumor weight)
to body weight. Tumor inhibition rate (D) was obtained
with mean tumor indices of drug group divided by mean
tumor indices of model group.
When the treatments were over, all animals were
deprived of food but allowed free access to water for
16 h. On the following morning, the mice were euthanized
for collection of the tumors and spleens, which were
immediately placed in 4% buffered paraformaldehyde and
fixed overnight. The obtained tumor tissues were
dehydrated through an ethanol gradient and embedded in
paraffin. Tissue sections (5 μm) were then dewaxed and
rehydrated. The sections were stained with hematoxylin
and eosin (HE) for observation.
Western blot analysis
Carcinoma cell line SMMC-7721 cells in the logarithmic
growth phase were seeded in 35 mm culture dishes at a
density of 3 × 105 cells/mL and incubated for 24 h.
Subsequently, the adherent cells were incubated with
different concentrations of bufothionine (90.62, 18.12,
or 3.62 ng/mL) for 48 h,while the control groups were
treated with culture medium containing 10% FBS.
The adherent cells were washed twice with ice-cold
phosphate-buffered saline (PBS), lysed with RIPA buffer
(RIPA buffer/protease inhibitors/EDTA = 100:1:1; Thermo
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scraper, and centrifuged for 15 min at 14,000 × g
under 4°C. The resulting supernatants containing the
protein fraction were stored at-80°C until analysis.
The protein concentrations were determined with a
Bicinchoninic Acid (BCA) Protein Assay Kit (Pierce,
USA) according to the manufacturer’s instructions.
Afterwards, all protein samples were mixed with Laemmli
loading buffer (Beyotime Institute of Biotechnology,
China), boiled for 3–5 min, and stored at-20°C until
analysis.
Equivalent amounts of proteins were subjected to 8%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and transferred to polyvinyl lidene difluoride membranes
(Beyotime Institute of Biotechnology, China). Subsequently,
the membranes were blocked with 5% skim milk (Beyotime
Institute of Biotechnology) and shaked at 80 r/min for 1 h
under room temperature on a shaker and incubated with
specific primary antibodies (1:1000 dilution in PBS) against
β-actin, Bcl-2, Bax, caspase-3, caspase-9, cyto-c, Bid, and
p53 (Santa Cruz Biotechnology Inc., USA) overnight at 4°C.
The membranes were washed three times with western
cleaning solution (Beyotime Institute of Biotechnology,
China), incubated with a horseradish peroxidase-conjugated
secondary antibody (1:15,000 dilution in ultrapure water)
for 30 min at room temperature in a dark place, and
washed three times with western cleaning solution. Finally,
immune-reactive proteins were detected by enhanced
chemo-luminescence (Odyssey Infrared Imaging System,
LI-COR Co. LTD, USA). In this experiment, β-actin was
used as an internal control to confirm that the amounts of
loaded protein were equal. All experiments were repeated
at least three times.
Statistical analysis
The results were expressed as the mean ± SD. Statistical
analyses were performed by one-way analysis of variance
(ANOVA) using SPSS 17.0 for Windows software (SPSS
Inc., USA). Bonferroni multiple comparison tests were
performed for post hoc pairwise comparisons. P values
less than 0.05 were considered statistically significant.
Data from at least three independent experiments were
used for statistical analysis. Dose-dependent manner was
visually determined.
Results
Effects of drugs on acute liver injury
Establishment of an acute liver injury model
After liver injury was induced by CCl4 (1.5 mL/kg), the
rats were euthanized and the liver tissues were removed
immediately. The normal livers had a bright color with
uniform texture (Figure 2A). On the other hand, the
injured livers exhibited visible necrosis with a pale color
(Figure 2B). The appearance of the rat livers in this trialdemonstrated that the acute liver injury model was
established.Weight analysis
The weight results showed that the growth rates of the
rats were normal during the first 7 days, with an average
growth of 8.65 g/d (Figure 2C). However, after acute
liver injury induced by CCl4, the increments in body
weight was arrested on day 8th, indicating that CCl4 might
contribute to weight loss. There were no significant
differences among the groups (P = 0.519). These findings
indicated that animals were consistent and suitable for
subsequent pharmacologic research.Effects of drugs on liver weight indices
Compared with normal group, the rat liver weight indices
in the Mod, BufoA, GLy and InjA group were significantly
increased (corresponding P values respectively 8.10 × 10-3,
2.19 × 10-4, 1.00 × 10-4, 8.80 × 10-5) (Figure 2D), indicating
the livers might swell after injury.Effects of drugs on liver biochemical markers
Compared with the normal group, ALT, AST, ALP and
TBIL values of Mod, BufoA, GLy and InjA group were
significantly elevated (corresponding P values for ALT were
8.11 × 10-5, 1.25 × 10-3, 1.18 × 10-4 and 1.01 × 10-2; for AST,
P values were 6.66 × 10-4, 1.32 × 10-4, 2.92 × 10-6, 1.93 × 10-3;
for ALP, P values were 1.26 × 10-4, 0.01, 0.483, 0.034 and for
TBIL, P values were 1.02 × 10-3, 6.35 × 10-3, 3.63 × 10-3,
6.04 × 10-2) (Figure 2E–H). This suggested that CCl4
induced liver injury and resulted in liver dysfunction.
Compared with the model group, ALT levels of
BufoA, GLy and InjA group were obviously decreased
(corresponding P values were 2.46 × 10-2, 8.17 × 10-4,
8.29 × 10-3) (Figure 2E), demonstrating that cinobufacini
injection and bufothionine could improve ALT marker.
Furthermore, although there was no statistic difference,
therapeutic groups also expressed tendency to decrease
other biochemical markers including AST, ALP and TBIL
(Figure 2F-H).Effects of drugs on liver histological morphology
In normal liver cells, the histological morphology and
the nucleoplasm was uniform (Figure 3A). In con-
trast to the normal group, the hepatocytes exhibited
necrosis after liver injury and the nucleoplasm was
severely contracted (Figure 3B). Through the treat-
ment with drugs, the hepatocyte morphology was im-
proved. The sequence of hepatocyte improvement was as
follows: bufoA (Figure 3C) > Gly (Figure 3D) > InjA
(Figure 3E).
Figure 2 (See legend on next page.)
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Figure 2 Effects of drugs on liver morphology, weight and biochemical markers after the CCl4 injury. All rats were arbitrarily divided into
five groups (n = 10): normal group (Nor), model group (Mod), bufothionine group (9.77 mL/kg) (BufoA), glycyrrhizin group (Gly) and cinobufacini
injection group (3.42 mL/kg) (InjA). They were treated once daily at a fixed time for 8 d. On the 8th day CCl4 (1.5 mL/kg) was administered to
induce acute liver injury except in the normal group (A: normal rat liver B: rat liver model induced by CCl4). Then they fasted with free access to
water. On the 9th day, all rats in each group were anaesthetized to collect blood. Weights data during whole experiment were recorded (C). Liver
weight indice was calculated as the ratio of liver weight to weight (D). Serum levels of ALT (E), AST (F), ALP (G) and TBIL (H) were determined. AST:
aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; TBIL: total bilirubin. All data were represented mean ± SD (n = 10).
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Establishment of an H22-tumor-bearing mouse model
At 5–7 days after inoculation of H22 cells into the abdom-
inal cavity of a mouse, yellow ascites occurred (Figure 4A).
The ascites fluids were extracted, diluted, and centrifuged.
The obtained pellets were diluted with normal saline and
subcutaneously injected into the right flank of each mouse.
After several days, tumors developed under the right flank
(Figure 4B), while mice without inoculation did not develop
tumors (Figure 4C). These findings indicated that the
tumor-bearing mouse model was successfully established.Figure 3 Effects of drugs on liver histological morphology after CCl4
without induction by CCl4. Other rats were pretreated with normal saline (B
(D), cinobufacini injection (3.42 mL/kg) (E) for 8 days before 1.5 mL/kg CCl
hematoxylin and eosin staining. . In normal liver cells cell morphology was
After liver injury, hepatocytes exhibited necrosis and the nucleoplasm wasEffects of drugs on weight, spleen weight, and tumor
weight
After inoculation, mice weight increased steadily during
the therapeutic period, except for the 5-Fu group. The
adverse reactions of 5-Fu chemotherapy were more
serious than those of cinobufacini treatment, e.g., diarrhea
and weight loss (Figure 5A).
The spleen indices in the therapeutic groups were
lower than those in the Mod group (Figure 5B). Among
all of the drugs examined, the effect of 5-Fu was the
most significant (P = 0.0124). BufoB (P = 0.04) and InjBtreatment. Normal rats (A) were administrsted by normal saline
), bufothionine (9.77 mL/kg) (C), compound glycyrrhizin injection
4 was administered. Hepatic tissue was collected and subjected to
normal and the nucleoplasm was uniform (indicated by red arrow).
severely contracted (indicated by yellow arrow).
Figure 4 Establishment of H22 tumor -bearing mice model. H22
cells were injected into the abdominal cavity of a mouse. After several
days, ascites occurred (A). Ascites fluids were injected into the right
flank of each mouse. After several days, tumor developed under the
right flank (B). Mice without inoculation did not develop tumors (C).
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spleen swelling.
The tumor indices in the therapeutic groups were
lower than those in the Mod group (Figure 5C). Among
all of the drugs tested, the effect of 5-Fu was the strongest,
with a tumor inhibition rate of 86.40% (Figure 5D). InjBand bufoB group also decreased tumor weight with
77.93% and 65.16% inhibition rates (Figure 5D).
Effects of drugs on liver histological morphology
In contrast to the Mod group (Figure 6A), the tumor tissues
in the therapeutic groups appeared hollow and exhibited
necrosis (Figure 6B–D). Among all of the drugs examined,
the necrotic areas of tumor tissue in the BufoB group
(Figure 6D) were larger than those in all other groups,
followed by 5-Fu (Figure 6B) and InjB (Figure 6C).
Effects of bufothionine on the mitochondria-mediated
apoptosis pathway
To explore the involvement of mitochondria-mediated
apoptosis induced by bufothionine in SMMC-7721 cells,
the expressions of Bcl-2, Bax, caspase-3, caspase-9, Bid,
cyto-c, and p53 were measured by western blot analyses
(Figure 7). The results revealed that, bufothionine showed
a trend toward up-regulating the expressions of p53
(at the low, medium and high concentration correspond-
ing P values were respectively 0.142,0.0257 and 0.0162),
caspase-3 (P = 0.246, 0.0267 and 0.0236), cyto-c (P = 0.276,
0.0343 and 0.0429), Bid (P = 0.0125, 0.0395 and 0.0132) and
Bax (P = 0.563, 0.0492 and 0.0357) in a dose-dependent
manner, down-regulating the level of Bcl-2 (P = 0.0232,
0.0178 and 0.0464), but had no significant effects on
caspase-9 (P = 0.253, 0.147 and 0.287).
Discussion
Large numbers of papers about cinobufacini focused on
bufodienolides belonging to the cardiotonic steroids
[19,20]. To avoid adverse effects of steroids, we focused
on the alkaloid bufothionine in this study.
According to clinical practice, cinobufacini injection
can relieve liver dysfunctions [6]. For the CCl4-induced
liver injury model, the dosage of CCl4 was the key point
to the degree of liver injury, e.g., when the dose was
>5 mL/kg body weight, the rats were likely to die within
a few hours. After several trials, the dosage of 1.5 mL/kg
was considered to be an appropriate dosage. In this
model, the results for biochemical markers such as ALT
and HE staining showed that bufothionine could improve
liver injury.
To our knowledge, CCl4 is a well-known hepatotoxic
chemical. The CCl3
. free radicals from CCl4 by CYP450
transform, can result in peroxidation of unsaturated
fatty acid in the cytoplasm and organelle membranes.
The concentrations of calcium ions in cytoplasm are
elevated, the cytoskeletons are destroyed, the functions of
amino acids are damaged, and the nucleicacids become
mutated; and all of the above effects accelerate the death
of cells [17]. A possible mechanism for bufothionine to
protect liver functions may be associated with its allevi-
ation of injuries caused by free radicals.
Figure 5 Effects of drugs on weights. (A), spleen weight indices (B), tumor weight indices (C) and tumor inhibition rate (D) of H22 tumor bearing
mice. All H22 tumor bearing mice were treated with different drugs: normal group (Nor), model group (Mor), bufothionine group (8.02 mL/kg) (BufoB),
5-Fu group (5-Fu), cinobufacini injection group (5.14 mL/kg) (InjB). After ten days, weight (A), spleen weight and tumor weight of different groups were
recorded. Spleen weight indices (B) were expressed as the ratio of spleen weight to weight. Tumor weight indices (C) were expressed as the ratio of
tumor weight difference (final tumor weight - initial tumor weight) to body weight. Tumor inhibition rate (D) was obtained with mean tumor indices
of drug group divided by mean tumor indices of model group. Data were represented as mean ± SD (n = 10).
Figure 6 Effects of drugs on tumor histology for H22 tumor -bearing mice. Normal saline were administrated to normal rats (A).5-Fu (B),
cinobufacini injection (5.14 mL/kg) (C) and bufothionine (8.02 mL/kg) (D) were respectively administrated to H22 tumor-bearing mice. After 10 days,
rats were sacrificed and tumors were removed. The tissues were dehydrated, embedded, sliced and stained with HE staining for observation.
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Figure 7 Effects of bufothionine on the expressions of apoptosis relative proteinsSMMC-7721 cells were treated with different concentration
of bufothionine for 48 h (A). Protein of cells were extracted and protein express of p53 (B), caspase-9 (C), caspase-3 (D), bcl-2 (E), bid (F), bax (G) and
cyto-c (H) was analyzed by Western blot, respectively. All experiments were repeated at least three times. Data were represented as mean ± SD (n = 3).
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Xie et al. Chinese Medicine  (2015) 10:5 Page 10 of 11Cinobufacini is a Chinese medicine extract for cancer
treatment [5,7]. Here, we investigated antitumor effects
of its reparation–cinobufacini injection. The H22-tumor-
bearing mouse model was established according to the
literature [21]. It should be noted that the viability of
ascites cells was crucial in this trial. At 5–7 days after
intraperitoneal injection, the yellow ascites fluids should be
collected. If time was delayed, the ascites fluids would
become red and the viability of the cells might decrease
and result in failure of the experiment. Under this model,
bufothionine expressed the effects of inhibit tumor growth.
The antitumor functions of bufadienolides might be asso-
ciated with inhibition of cell proliferation [22], induction of
apoptosis [23], disruption of the cell cycle [24], promotion
of cell differentiation [25], and suppression of angiogenesis
[26]. Among these stages, induction of apoptosis was a crit-
ical step for bufadienolides. Moreover, the mitochondria-
mediated apoptosis pathway was important [19,27].
In the mitochondria-mediated apoptosis pathway, an
apoptotic stimulus is followed by release of cyto-c from
mitochondria into the cytosol. Following its release,
cyto-c forms a complex in the cytoplasm, which then acti-
vates procaspase-9 and in turn activates procaspase-3 [28],
leading to DNA fragmentation and triggering apoptosis
[29]. Bufothionine could promote the release of cyto-c into
the cytosol, with up-regulation of its protein expression.
Moreover, caspase activity analyses demonstrated that
caspase-3 was activated after cinobufacini treatment.
Bufothionine could up-regulate the expression of
the pro-apoptotic protein Bax and down-regulate the
expression of the anti-apoptotic protein Bcl-2. Members
of the Bcl-2 protein family, such as Bax and Bcl-2, are the
most prominent players in the mitochondria-mediated
apoptosis pathway [30]. Bax is a pro-apoptotic protein
[31], while Bcl-2 is an anti-apoptotic protein [32].
The present study also indicated that bufothionine up-
regulated the expression of p53. P53 is an important
protein in cell apoptosis. Either loss or mutation of p53
leads to gain-of-function toward cell migration, invasion
and metastasis [33].
Conclusion
Bufothionine induced the proteins for the mitochondria-
mediated apoptosis that inhibits liver tumors and protects
the liver against acute injury.
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